by Alison Bass | Jul 3, 2012 | antidepressants, antipsychotic drugs, clinical trials, drug marketing, patient care, pharmaceutical industry, scientific journal retractions, scientific misconduct, suicide rates, whistleblowing
I was glad to see that the New York Times’ reporters covering GlaxoSmithKline’s $3 billion settlement tipped their hat to former New York Attorney General Eliot Spitzer. After all, it was his crew and specifically a pioneering attorney by the name of Rose...
by Alison Bass | Jun 29, 2012 | prostitution, public health, sex trafficking
A coalition of folks opposed to sex trafficking paraded last week in front of the Village Voice headquarters in Cooper Square, urging the shutdown of its classified website Backpage on the grounds that its online ads foster the trafficking of under-age prostitutes....
by Alison Bass | Jun 15, 2012 | Uncategorized
Just as Canada has provided us with a model for affordable health care, our neighbors to the north may also be leading the way on another key issue: reducing the spread of AIDS and other sexually transmitting diseases. A few months ago, a federal appeals court in...
by Alison Bass | Jun 7, 2012 | biotech industry, clinical trials, conflicts of interest, pharmaceutical industry, Uncategorized
Senator Charles Grassley is upping the ante on the controversy surrounding the Vertex pharmaceutical executives who cashed in on overstated clinical trial data — see my blog from last week. According to The Boston Globe, which broke the Vertex story, Grassley...
by Alison Bass | May 30, 2012 | biotech industry, clinical trials, conflicts of interest, drug marketing, pharmaceutical industry, Uncategorized
Senior executives at Vertex Pharmaceuticals made millions of dollars each by selling company stock in the days after the Cambridge-based pharmaceutical reported promising clinical trial data on an experimental drug for cystic fibrosis. And then weeks after they cashed...
